HOTH - Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday? | Benzinga
Tuesday, Hoth Therapeutics Inc (NASDAQ:HOTH) unveiled positive preclinical research showcasing the potential of HT-ALZ, an Alzheimer’s disease therapeutic.
Targeting the Substance P/Neurokinin 1 Receptor pathway, the company says that HT-ALZ emerges as a promising solution for combating neuroinflammation and cognitive deficits associated with Alzheimer’s Disease.
By specifically antagonizing the NK1 receptor, HT-ALZ reduces soluble A? levels in the brain’s interstitial fluid, significantly diminishes anxiety-like behavior, and enhances cognitive function in preclinical models.
The research presents compelling evidence of HT-ALZ’s capacity to improve memory tasks ...